Skip to menu Skip to content Skip to footer
Professor David Johnson
Professor

David Johnson

Email: 
Phone: 
+61 7 3176 5050

Overview

Background

Professor David Johnson PSM

MB BS (Hons, Univ Medal), PhD (Syd), DMed(Res), FASN, FISN, FAHMS, FRACP

Department of Kidney and Transplant Services, Division of Medicine, Building 31, Princess Alexandra Hospital

david.johnson2@health.qld.gov.au

David Johnson is full-time Director of the Metro South Kidney and Transplant Service (MSKATS) and Medical Director of the Queensland Kidney Transplant Service (QKTS) at Princess Alexandra Hospital, Professor of Medicine and Professor of Population Health at University of Queensland, and Director of the Centre for Kidney Disease Research in Brisbane, Australia. He has a number of international leadership responsibilities, including Co-Chair of the International Society of Nephrology Global Kidney Health Atlas (ISN GKHA), Co-Chair of the International Society for Peritoneal Dialysis (ISPD) Guidelines on Peritonitis Prevention and Treatment, Co-Chair of the Global PDOPPS Steering Committee, Chair of SONG-PD, Immediate Past President of the Australian and New Zealand Society of Nephrology (ANZSN), Past President of the ISPD (2018-2020), Past Councillor of the ISN (2013-2019), and member of the ISN-ACT, ISN Research and ISN Monitor groups. He is currently a chair or member of 11 national and 7 international guideline groups and is ranked by Expertscape as the “top-rated expert in dialysis in the world during the years 2013-2023.” He has influenced policy and practice through his leadership as Deputy Chair of the Australian Better Evidence And Translation in Chronic Kidney Disease (BEAT-CKD) program, Deputy Chair of the Australasian Kidney Trials Network (AKTN), Chair of the Primary Healthcare Education Advisory Committee to Kidney Health Australia (PEAK), Co-Chair of the Australasian Creatinine and eGFR Consensus Working Party, Co-Chair of the Australasian Proteinuria Consensus Working Party, Member and Past-Chair of the ANZDATA Registry Peritoneal Dialysis Working Group, and Past-Chair of the Queensland Statewide Renal Clinical Network.

Having published over 1200 original manuscripts in peer-reviewed journals and presented over 550 abstracts at national and international scientific meetings, he brings critical expertise in designing and conducting multi-centre, multi-national randomised controlled trials (RCTs), developing national and international registries, using innovative research methodologies (such as registry-based RCTs) and implementing trial findings into practice. He has held lead roles in high-impact, large, multi-centre RCTs that have informed global clinical practice, including CKD-FIX, IDEAL, balANZ, HONEYPOT, TESTING, HERO, and IMPENDIA. He is currently principal investigator of the TEACH-PD and INCH-HD trials, and chair of the PHOSPHATE Trial Global Steering Committee. He helped establish the Australian Peritonitis Registry and led the highly successful National PD Peritonitis Quality Improvement Project, which reduced national peritonitis rates by two-thirds. He also led the universal implementation of automated laboratory reporting of eGFR in ANZ which increased national detection rates by 40%.

He has won numerous awards for both his basic science and clinical research science studies, including the ANZSN TJ Neale Award for “outstanding contributions to nephrologic science” (2005), the US National Kidney Foundation International Distinguished Medal (2014), the Canadian Society of Nephrology Dimitrios Oreopoulos Award (2017) and the Asia-Pacific Society of Nephrology Priscilla Kincaid-Smith Award (2021). He was a Queensland finalist in the Australian of the Year Awards in 2009 and was awarded a Public Service Medal by the Governor-General of Australia in 2011 for outstanding public service, particularly research into the early detection and management of kidney disease.

Availability

Professor David Johnson is:
Available for supervision

Fields of research

Qualifications

  • Doctoral Diploma, The University of Queensland

Research interests

  • Chronic kidney disease

  • Peritoneal dialysis

  • Haemodialysis

  • Kidney transplantation

Research impacts

Chronic kidney disease (CKD) is increasingly recognised as a major public health problem in Australia and worldwide. The Centre for Kidney Disease Research (CKDR) is one of Australia’s leading kidney disease research centres with an international reputation for excellence in research. The researchers of the CKDR are working at the forefront of global trends in research to understand the cellular and molecular basis of kidney disease and to trial innovative new clinical treatments to improve the health and well-being of people with kidney disease. Renowned for its studies in acute and chronic kidney disease and kidney cancers, the CKDR has particular expertise in translating results from laboratory and clinical sciences for application to improve public health outcomes.

The vision of our research program is to increase global equity in access to affordable, sustainable, quality kidney care. Some of the major achivements of the research program to date have been determining the ideal time to commence dialysis, the role of statins in improving cardiovascular outcomes in patients with kidney disease, biocompatible peritoneal dialysis fluid use, glucose-sparing peritoneal dialysis prescriptions for people with diabetes and kidney failure, mupirocin versus honey prophylaxis in peritoneal dialysis, anaemia treatment in chronic kidney disease, the role of allopurinol in preventing CKD progression, and the role of oral steroids in IgA nephropathy. A significant dataset has also been generated from the largest health survey conducted in the world (Global Kidney Health Atlas 2017, 2019, 2023). It is available to researchers globally, has informed WHO policy, underpinned advocacy activities to put kidney health on the international agenda; allowed benchmarking of progress for individual countries; enabled longitudinal evaluation of the organisation and structure of kidney care globally to inform policy, and has been used to facilitate policy changes and care strategies in international jurisdictions (Mexico, Caribbean, Fiji, Malaysia). The program has standardised practice and halved pertioneal dialysis-related infection. Implementation of multi-pronged strategies, now emulated by Canada and USA, led to establishment of a peritonitis registry, a national quality improvement program and publication of >50 papers on peritonitis, which influenced international PD guidelines. Highly cited and adopted internationally, the International Society for Pertioneal Dialysis (ISPD Guidelines) are considered the gold standard by other kidney care guideline groups. Finally, significant knowledge has been generated through the internationally endorsed Stanardised Outcomes in NephroloGy (SONG) initiative which uses shared priorities of patients, carers and clinicians to identify core outcome measures for kidney research. The ultimate result of the research program will be patient-prioritised research questions with outputs of critical importance to the global kidney care community that will inform international guidelines and policy, build capacity for international research collaboration and leadership, facilitate kidney care quality monitoring and reporting, and improve health outcomes for people with chronic kidney disease.

Works

Search Professor David Johnson’s works on UQ eSpace

1418 works between 1993 and 2025

681 - 700 of 1418 works

2016

Journal Article

The stress response of human proximal tubule cells to cadmium involves up-regulation of haemoxygenase 1 and metallothionein but not cytochrome P450 enzymes

Boonprasert, Kanyarat, Satarug, Soisungwan, Morais, Christudas, Gobe, Glenda C., Johnson, David W., Na-Bangchang, Kesara and Vesey, David A. (2016). The stress response of human proximal tubule cells to cadmium involves up-regulation of haemoxygenase 1 and metallothionein but not cytochrome P450 enzymes. Toxicology Letters, 249, 5-14. doi: 10.1016/j.toxlet.2016.02.016

The stress response of human proximal tubule cells to cadmium involves up-regulation of haemoxygenase 1 and metallothionein but not cytochrome P450 enzymes

2016

Journal Article

The peritoneal dialysis outcomes and practice patterns study (Pdopps): unifying efforts to inform practice and improve global outcomes in peritoneal dialysis

Perl, Jeffrey, Davies, Simon J., Lambie, Mark, Pisoni, Ronald L., McCullough, Keith, Johnson, David W., Sloand, James A., Prichard, Sarah, Kawanishi, Hideki, Tentori, Francesca and Robinson, Bruce M. (2016). The peritoneal dialysis outcomes and practice patterns study (Pdopps): unifying efforts to inform practice and improve global outcomes in peritoneal dialysis. Peritoneal Dialysis International, 36 (3), 297-307. doi: 10.3747/pdi.2014.00288

The peritoneal dialysis outcomes and practice patterns study (Pdopps): unifying efforts to inform practice and improve global outcomes in peritoneal dialysis

2016

Journal Article

Long-term outcomes of end-stage kidney disease for patients with IgA nephropathy: a multi-centre registry study

Zhang, Lei, Liu, Xusheng, Pascoe, Elaine M., Badve, Sunil V., Boudville, Neil C., Clayton, Philip A., De Zoysa, Janak, Hawley, Carmel M., Kanellis, John, McDonald, Stephen P., Peh, Chen Au, Polkinghorne, Kevan R. and Johnson, David W. (2016). Long-term outcomes of end-stage kidney disease for patients with IgA nephropathy: a multi-centre registry study. Nephrology, 21 (5), 387-396. doi: 10.1111/nep.12629

Long-term outcomes of end-stage kidney disease for patients with IgA nephropathy: a multi-centre registry study

2016

Journal Article

Decreased apoptosis repressor with caspase recruitment domain confers resistance to sunitinib in renal cell carcinoma through alternate angiogenesis pathways

Gobe, Glenda C., Ng, Keng Lim, Small, David M., Vesey, David A., Johnson, David W., Samaratunga, Hemamali, Oliver, Kimberley, Wood, Simon, Barclay, Johanna L., Rajandram, Retnagowri, Li, Li and Morais, Christudas (2016). Decreased apoptosis repressor with caspase recruitment domain confers resistance to sunitinib in renal cell carcinoma through alternate angiogenesis pathways. Biochemical and Biophysical Research Communications, 473 (1), 47-53. doi: 10.1016/j.bbrc.2016.03.048

Decreased apoptosis repressor with caspase recruitment domain confers resistance to sunitinib in renal cell carcinoma through alternate angiogenesis pathways

2016

Journal Article

Opponent's comments

Nadeau-Fredette, Annie-Claire and Johnson, David W. (2016). Opponent's comments. Nephrology Dialysis Transplantation, 31 (4), 524-524. doi: 10.1093/ndt/gfw031a

Opponent's comments

2016

Journal Article

Assessment of current practice and barriers to antimicrobial prophylaxis in peritoneal dialysis patients

Campbell, Denise J., Brown, Fiona G., Craig, Jonathan C., Gallagher, Martin P., Johnson, David W., Kirkland, Geoffrey S., Kumar, Subramanian K., Lim, Wai H., Ranganathan, Dwarakanathan, Saweirs, Walaa, Sud, Kamal, Toussaint, Nigel D., Walker, Rowan G., Williams, Lesley A., Yehia, Maha and Mudge, David W. (2016). Assessment of current practice and barriers to antimicrobial prophylaxis in peritoneal dialysis patients. Nephrology Dialysis Transplantation, 31 (4), 619-627. doi: 10.1093/ndt/gfv115

Assessment of current practice and barriers to antimicrobial prophylaxis in peritoneal dialysis patients

2016

Journal Article

Con: buttonhole cannulation of arteriovenous fistulae

Nadeau-Fredette, Annie-Claire and Johnson, David W. (2016). Con: buttonhole cannulation of arteriovenous fistulae. Nephrology Dialysis Transplantation, 31 (4), 525-528. doi: 10.1093/ndt/gfw030

Con: buttonhole cannulation of arteriovenous fistulae

2016

Journal Article

The role of the gastrointestinal tract and microbiota on uremic toxins and chronic kidney disease development

Briskey, David, Tucker, Patrick, Johnson, David W. and Coombes, Jeff S. (2016). The role of the gastrointestinal tract and microbiota on uremic toxins and chronic kidney disease development. Clinical and Experimental Nephrology, 21 (1), 1-9. doi: 10.1007/s10157-016-1255-y

The role of the gastrointestinal tract and microbiota on uremic toxins and chronic kidney disease development

2016

Journal Article

Longitudinal trend in lipid profile of incident peritoneal dialysis patients is not influenced by the use of biocompatible solutions

Cho, Yeoungjee, Buchel, Janine, Steppan, Sonja, Passlick-Deetjen, Jutta, Hawley, Carmel M., Dimeski, Goce, Clarke, Margaret and Johnson, David W. (2016). Longitudinal trend in lipid profile of incident peritoneal dialysis patients is not influenced by the use of biocompatible solutions. Peritoneal Dialysis International, 36 (2), 146-153. doi: 10.3747/pdi.2014.00291

Longitudinal trend in lipid profile of incident peritoneal dialysis patients is not influenced by the use of biocompatible solutions

2016

Journal Article

Indoxyl sulphate and kidney disease: causes, consequences and interventions

Ellis, Robert J., Small, David M., Vesey, David A., Johnson, David W., Francis, Ross, Vitetta, Luis, Gobe, Glenda C. and Morais, Christudas (2016). Indoxyl sulphate and kidney disease: causes, consequences and interventions. Nephrology, 21 (3), 170-177. doi: 10.1111/nep.12580

Indoxyl sulphate and kidney disease: causes, consequences and interventions

2016

Journal Article

Baseline characteristics of the omega-3 fatty acids (Fish oils) and aspirin in vascular access OUtcomes in REnal disease (FAVOURED) study

Viecelli, Andrea K., Pascoe, Elaine M., Polkinghorne, Kevan R., Hawley, Carmel M., Paul-Brent, Peta-Anne, Badve, Sunil V., Cass, Alan, Johnson, David W., Kerr, Peter G., Mori, Trevor A., Scaria, Anish, Hooi, Seong L., Ong, Meng L. and Irish, Ashley B. (2016). Baseline characteristics of the omega-3 fatty acids (Fish oils) and aspirin in vascular access OUtcomes in REnal disease (FAVOURED) study. Nephrology, 21 (3), 217-228. doi: 10.1111/nep.12573

Baseline characteristics of the omega-3 fatty acids (Fish oils) and aspirin in vascular access OUtcomes in REnal disease (FAVOURED) study

2016

Journal Article

Recent clinical trials of pharmacologic cardiovascular interventions in patients with chronic kidney disease: An update

Nataatmadja, Melissa, Cho, Yeoungjee, Fahim, Magid and Johnson, David W. (2016). Recent clinical trials of pharmacologic cardiovascular interventions in patients with chronic kidney disease: An update. Reviews on Recent Clinical Trials, 11 (1), 12-32. doi: 10.2174/1574887110666151026123235

Recent clinical trials of pharmacologic cardiovascular interventions in patients with chronic kidney disease: An update

2016

Journal Article

Filaggrin inhibits generation of CD1a neolipid antigens by house dust mite-derived phospholipase

Jarrett, Rachael, Salio, Mariolina, Lloyd-Lavery, Antonia, Subramaniam, Sumithra, Bourgeois, Elvire, Archer, Charles, Cheung, Ka Lun, Hardman, Clare, Chandler, David, Salimi, Maryam, Gutowska-Owsiak, Danuta, de la Serna, Jorge Bernardino, Fallon, Padraic G., Jolin, Helen, Mckenzie, Andrew, Dziembowski, Andrzej, Podobas, Ewa Izabela, Bal, Wojciech, Johnson, David, Moody, D. Branch, Cerundolo, Vincenzo and Ogg, Graham (2016). Filaggrin inhibits generation of CD1a neolipid antigens by house dust mite-derived phospholipase. Science Translational Medicine, 8 (325) 325ra18. doi: 10.1126/scitranslmed.aad6833

Filaggrin inhibits generation of CD1a neolipid antigens by house dust mite-derived phospholipase

2016

Journal Article

Focus on peritoneal dialysis training: working to decrease peritonitis rates

Zhang, Lei, Hawley, Carmel M. and Johnson, David W. (2016). Focus on peritoneal dialysis training: working to decrease peritonitis rates. Nephrology Dialysis Transplantation, 31 (2), 214-222. doi: 10.1093/ndt/gfu403

Focus on peritoneal dialysis training: working to decrease peritonitis rates

2016

Conference Publication

International Variations in the Experience of Patients On Peritoneal Dialysis (Pd) in the Peritoneal Dialysis Outcomes and Practice Patterns Study (Pdopps)

Finkelstein, Fredric O., Zhao, Junhui, Bieber, Brian, Jassal, S. Vanita, Morgenstern, Hal, Tsuchida, Kenji, Brown, Edwina, Johnson, David W. and Tentori, Francesca (2016). International Variations in the Experience of Patients On Peritoneal Dialysis (Pd) in the Peritoneal Dialysis Outcomes and Practice Patterns Study (Pdopps). 53rd ERA-EDTA Congress, Vienna Austria, May 21-24, 2016. United Kingdom: Oxford University Press.

International Variations in the Experience of Patients On Peritoneal Dialysis (Pd) in the Peritoneal Dialysis Outcomes and Practice Patterns Study (Pdopps)

2016

Conference Publication

Protease activated-receptor-2 induced inflammation and fibrosis is mediated in part through activation of transforming growth factor-beta signalling

Owens, E., Iyer, A., Morais, C., Lohman, R., Suen, J., Johnson, D., Nikolic-Paterson, D., Gobe, G., Fairlie, D. and Vesey, D. (2016). Protease activated-receptor-2 induced inflammation and fibrosis is mediated in part through activation of transforming growth factor-beta signalling. The 15th Asian Pacific Congress of Nephrology (APCN) and 52nd ANZSN ASM, Perth Western Australia, 17–21 September 2016. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/nep.12887

Protease activated-receptor-2 induced inflammation and fibrosis is mediated in part through activation of transforming growth factor-beta signalling

2016

Conference Publication

Randomised Controlled Trial to Determine the Efficacy of Prescribed Fluid Intake to Reduce Progression in Adpkd (Prevent-Adpkd)

Wong, A., Allman-Farinelli, M., Erickson, B., Foster, S., Grantham, J., Haloob, I, Harris, D., Hawley, C., Johnson, D., Lee, V, Mai, J., Peduto, A., Rangan, A., Roger, S., Sud, K., Torres, V and Rangan, G. (2016). Randomised Controlled Trial to Determine the Efficacy of Prescribed Fluid Intake to Reduce Progression in Adpkd (Prevent-Adpkd). The 15th Asian Pacific Congress of Nephrology (APCN) and 52nd ANZSN ASM, Perth, Western Australia, 17–21 September 2016. Hoboken, NJ United States: Wiley-Blackwell.

Randomised Controlled Trial to Determine the Efficacy of Prescribed Fluid Intake to Reduce Progression in Adpkd (Prevent-Adpkd)

2016

Book Chapter

Treatment of Hepatitis B in patients with Chronic Kidney Disease

Chan, Samuel, Fahim, Magid A., Macdonald, Graeme A. and Johnson, David W. (2016). Treatment of Hepatitis B in patients with Chronic Kidney Disease. Hepatitis B Treatment. (pp. 2-49) Telangana, India: Avid Science.

Treatment of Hepatitis B in patients with Chronic Kidney Disease

2016

Conference Publication

Developing a set of core outcomes for trials in haemodialysis: an international Delphi survey

Evangelidis, N., Tong, A., Manns, B., Hemmelgarn, B., Wheeler, D., Tugwell, P., Crowe, S., Harris, T., Van Biesen, W., Winkelmayer, W., Sautenet, B., O'Donaghue, D., Tam-Tham, H., Youssouf, S., Mandayam, S., Ju, A., Hawley, C., Pollock, C., Harris, D., Johnson, D., Rifkin, D., Tentori, F., Agar, J., Polkinghorne, K., Gallagher, M., Kerr, P., Mcdonald, S., Howell, M. and Craig, J. (2016). Developing a set of core outcomes for trials in haemodialysis: an international Delphi survey. 15th Asian Pacific Congress of Nephrology (APCN) and 52nd ANZSN ASM, Perth, Western Australia, 17–21 September 2016. HOBOKEN: WILEY-BLACKWELL.

Developing a set of core outcomes for trials in haemodialysis: an international Delphi survey

2016

Journal Article

Higher dialysate matrix metalloproteinase-2 levels are associated with peritoneal membrane dysfunction

Cho, Yeoungjee, Johnson, David W., Vesey, David A., Hawley, Carmel M., Pascoe, Elaine M., Clarke, Margaret and Topley, Nicholas (2016). Higher dialysate matrix metalloproteinase-2 levels are associated with peritoneal membrane dysfunction. Peritoneal Dialysis International, 36 (1), 16-25. doi: 10.3747/pdi.2013.00274

Higher dialysate matrix metalloproteinase-2 levels are associated with peritoneal membrane dysfunction

Funding

Current funding

  • 2023 - 2028
    INCremental dialysis to improve Health in people starting HaemoDialysis (INCH-HD)
    NHMRC MRFF CTA - Clinical Trials Activity
    Open grant
  • 2022 - 2028
    REMIT: An international, multi-centre, randomised clinical trial to compare treatment regimens in Primary Membranous Nephropathy (MRFF Grant administered by The University of Adelaide)
    University of Adelaide
    Open grant
  • 2021 - 2026
    Centre of Research Excellence: Partnering with patients with chronic kidney disease to transform care and outcomes (CRE-PACT) (administered by University of Sydney)
    University of Sydney
    Open grant
  • 2021 - 2028
    An adaptive, randomised controlled trial to treat polyomavirus infections (BKPyV) in kidney and kidney pancreas transplant recipients (BEAT-BK) trial (MRFF RCRDUN led by USyd)
    University of Sydney
    Open grant
  • 2021 - 2025
    Increasing global equity in access to end-stage kidney disease care through better peritoneal dialysis affordability, practice, quality and outcomes
    NHMRC Investigator Grants
    Open grant
  • 2020 - 2027
    Implementation of Metformin theraPy to Ease DEcline of kidney function in PKD - the IMPEDE-PKD trial
    NHMRC MRFF - Rare Cancers, Rare Diseases and Unmet Need
    Open grant
  • 2020 - 2027
    Structured exercise program to reduce fatigue in patients receiving dialysis: a preference-stratified adaptive trial (M-FIT) (MRFF RCRDUN led by University of Sydney)
    University of Sydney
    Open grant
  • 2020 - 2025
    Teaching to improve health outcomes for peritoneal dialysis: The TEACH-PD Trial (HRC New Zealand)
    University of Otago
    Open grant
  • 2020 - 2025
    The GOAL Trial: Comprehensive geriatric assessment for frail older people with chronic kidney disease to increase attainment of patient-identified goals: A cluster randomised controlled trial
    NHMRC Targeted Research
    Open grant
  • 2019 - 2025
    The TEACH-PD study: a Targeted Education ApproaCH to improve Peritoneal Dialysis outcomes
    NHMRC MRFF - Rare Cancers, Rare Diseases and Unmet Need
    Open grant

Past funding

  • 2022 - 2023
    A mixed-methods study to evaluate the trust and confidence in telehealth in chronic kidney disease
    University of Queensland In-kind/Indirect Funding
    Open grant
  • 2021 - 2023
    Patient perspectives and involvement in co-design of a trial evaluating interventions to improve gut health in peritoneal dialysis - GUT PD Study (ISPD grant led by Eastern Institute of Technology)
    Eastern Institute of Technology
    Open grant
  • 2021 - 2024
    Better Evidence and Translation In Chronic Kidney Disease (BEAT-CKD) (administered by SAHMRI)
    South Australian Health and Medical Research Institute Limited
    Open grant
  • 2021 - 2025
    Pharmacy-based screening and quality use of medicines in kidney disease (MRFF Grant administered by The University of Sydney).
    University of Sydney
    Open grant
  • 2019 - 2020
    PDOPPS ANZDATA Linkage Project.
    Fresenius Medical Care Australia Pty Ltd
    Open grant
  • 2019 - 2021
    A Targeted Education ApproaCH to improve Peritoneal Dialysis outcomes - Cluster Randomised Controlled Trial (MSH Research Support Scheme Project Grant administered by MSHHS)
    Metro South Hospital and Health Service
    Open grant
  • 2018 - 2020
    IMPEDE-PKD (Implementation of Metformin therapy to Ease Decline of kidney function in PKD). A Clinical Trial Investigating Metformin to slow the progression of renal dysfunction in ADPKD
    PKD Foundation of Australia Limited
    Open grant
  • 2018 - 2020
    The TEACH-PD study: a Targeted Education ApproaCH to improve Peritoneal Dialysis outcomes
    Metro South Hospital and Health Service
    Open grant
  • 2018 - 2022
    Targeted Education Approach to Improve Peritoneal Dialysis Outcomes (TEACH-PD) - A Cluster RCT
    Baxter Healthcare Pty Ltd
    Open grant
  • 2016 - 2019
    The TEACH-PD pilot Study
    Baxter Healthcare Pty Ltd
    Open grant
  • 2016 - 2021
    Better evidence, better care and outcomes for people with chronic kidney disease (NHMRC Program Grant administered by Flinders University)
    Flinders University
    Open grant
  • 2015 - 2019
    The CKD-FIX trial
    Waitemata District Health Board
    Open grant
  • 2015
    Understanding the role of lymph node stromal microenvironment in renal cell carcinoma progression: Phase 2 - identifying personalized therapeutic strategies
    UQ-Ochsner Seed Fund for Collaborative Research - DVCR funds
    Open grant
  • 2014 - 2021
    Evaluation of the integrated home dialysis
    Baxter Healthcare Pty Ltd
    Open grant
  • 2014 - 2018
    The Australian Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS)
    NHMRC Project Grant
    Open grant
  • 2013 - 2019
    Controlled trial of slowing of Kidney Disease progression From the Inhibition of Xanthine oxidase (CKD-FIX): A double-blind, randomised, placebo-controlled trial
    NHMRC Project Grant
    Open grant
  • 2013 - 2017
    The SIGNAL Trial: Steroids in ImmunoGlobulin A Nephropathy: Assessment of Long term outcomes (NHMRC Project Grant administered by University of Sydney)
    University of Sydney
    Open grant
  • 2012 - 2013
    The utility of matrix metalloproteinase-2 (MMP-2) to predict peritoneal injury in the incident PD population
    Kidney Health Australia
    Open grant
  • 2012 - 2014
    Serial NT-proBNP Monitoring for Predicting Major Cardiovascular Events in the Dialysis Population
    NHMRC Project Grant
    Open grant
  • 2011 - 2015
    A randomised, placebo-controlled trial of Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia in chronic kidney disease
    NHMRC Project Grant
    Open grant
  • 2011 - 2013
    Macrophages: A therapeutic target in peritoneal dialysis-induced fibrosis? (NHMRC Project Grant administered by Wesley Research Institute)
    Wesley Merdical Research
    Open grant
  • 2010 - 2013
    Enhancing erythropoietin therapy in ischaemia-reperfusion injury of heart and kidney
    NHMRC Project Grant
    Open grant
  • 2008 - 2011
    A randomised, placebo-controlled trial of oxpentifylline on haemoglobin levels in patients with erythropoietin-resistant anaemia
    AMGEN Australia Pty. Ltd.
    Open grant
  • 2008 - 2013
    HONEYPOT (A randomized controlled trial evaluation of antibacterial HOney versus Nasal Eradication of staphYlococci for the Prevention Of Tenckhoff infections in PD)
    Baxter Healthcare Pty Ltd
    Open grant
  • 2007 - 2010
    HERO (A randomized, placebo-controlled trial of oxpentifylline on haemoglobin levels in patients with erythropoietin-resistant anaemia)
    Janssen-Cilag Pty Limited (Janssen-Cilag Australia)
    Open grant
  • 2007 - 2012
    A randomised placebo-controlled trial of Oxpentifylline (Trental) in erythropoietin-resistant anaemia (ERA) in chronic kidney disease
    The Roche Foundation for Anemia Research
    Open grant
  • 2007 - 2010
    HONEYPOT (A randomised controlled trial of exit site application of Medihoney Antibacterial Wound Gel for the preventation of catheter-associated infections in peritoneal dialysis patients)
    Gambro Pty Ltd
    Open grant
  • 2006 - 2009
    Cytoprotection by erythropoietin in hypoxia-ischaemia of the kidney and brain
    NHMRC Project Grant
    Open grant
  • 2005 - 2016
    Australasian Kidney Trials Network (AKTN)
    NHMRC Enabling Grant
    Open grant
  • 2005 - 2011
    Australasian Clinical Trials Network in Nephrology (CTNN)
    Australian Kidney Foundation
    Open grant
  • 2003 - 2005
    Causes, assessment and treatment of dehydration in older people.
    NHMRCARC Ageing Well, Ageing Productively Program
    Open grant
  • 2003 - 2007
    Centre of Clinical Research Excellence in Cardiovascular Disease and Metabolic Disorders
    NHMRC Research Centre Grant
    Open grant
  • 2002
    Strategies for targeted renal delivery of viral vectors for controlled and long-term gene therapy against chronic renal failure
    University of Queensland Research Development Grants Scheme
    Open grant
  • 2001 - 2002
    Applying anti-apoptotic benefits of BCL-XL in the ischaemia-reperfusion injured kidney
    Mayne Bequest Fund
    Open grant
  • 2000 - 2002
    Effects of risk factor control on atherosclerosis, vasoreactivity and cardiac ischemia in patients on dialysis
    NHMRC Project - Priming Grant
    Open grant

Supervision

Availability

Professor David Johnson is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

Completed supervision

Media

Enquiries

For media enquiries about Professor David Johnson's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au